journal article·2023-06-13Open access

In Vitro Characterization and Real-Time Label-Free Assessment of the Interaction of Chitosan-Coated Niosomes with Intestinal Cellular Monolayers

Elena Scurti, João Pedro Martins, Christian Celia, Paola Palumbo, Francesca Lombardi, Dalila Iannotta, Luisa Di Marzio, Hélder A. Santos, Tapani Viitala

Langmuir· Volume 39· Issue 23

Abstract

High Resolution Image Download MS PowerPoint Slide In vitro cell-based characterization methods of nanoparticles are generally static and require the use of secondary analysis techniques and labeling agents. In this study, bare niosomes and chitosan-coated niosomes (chitosomes) and their interactions with intestinal cells are studied under dynamic conditions and without fluorescent probes, using surface plasmon resonance (SPR)-based cell sensing. Niosomes and chitosomes were synthesized by using Tween 20 and cholesterol in a 15 mM:15 mM ratio and then characterized by dynamic light scattering (DLS). DLS analysis demonstrated that bare niosomes had average sizes of ∼125 nm, polydispersity index (PDI) below 0.2, and a negative zeta (ζ)-potential of −35.6 mV. In turn, chitosomes had increased sizes up to ∼180 nm, with a PDI of 0.2–0.3 and a highly positive ζ-potential of +57.9 mV. The viability of HT29-MTX, Caco-2, and Caco-2/HT29-MTX cocultured cells showed that both niosomes and chitosomes are cytocompatible up to concentrations of 31.6 μg/mL for at least 240 min. SPR analysis demonstrated that chitosomes interact more efficiently with HT29-MTX, Caco-2, and Caco-2/HT29-MTX cocultures compared to bare niosomes. The resulting SPR measurements were further supported by confocal microscopy and flow cytometry studies, which demonstrated that this method is a useful complementary or even alternative tool to directly characterize the interactions between niosomes and in vitro cell models in label-free and real-time conditions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Microfluidic and Bio-sensing Technologies · Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki 00014, Finland

Department of Pharmacy, University of Chieti − Pescara “G. d’Annunzio”, Chieti 66100, Italy

Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, Kaunas 44307, Lithuania

Department of Life, Health & Environmental Sciences, University of L’Aquila, L’Aquila 67100, Italy

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia

Department of Biomedical Engineering, University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, Groningen 9713, The Netherlands

W.J. Kolff Institute for Biomedical Engineering and Materials Science, University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, Groningen 9713 The Netherlands

Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland

Funding

Sigrid Juséliuksen Säätiö · Erasmus+ · Universitair Medisch Centrum Groningen · Academy of Finland · European Social Fund · Ministero dell'Istruzione, dell'Università e della Ricerca · Azione I.1 · Dottorati Innovativi con Caratterizzazione Industriale

References (45)

Show source-provided references
1. 10.1152/physrev.00015.201610.1152/physrev.00015.2016 ↗
2. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
3. 10.1021/bm900266r10.1021/bm900266r ↗
4. 10.3390/s13111534810.3390/s131115348 ↗
5. 10.3390/s15051048110.3390/s150510481 ↗
6. 10.1016/j.jaerosci.2008.06.00610.1016/j.jaerosci.2008.06.006 ↗
7. 10.1016/j.ijpharm.2015.08.07110.1016/j.ijpharm.2015.08.071 ↗
8. 10.1371/journal.pone.007219210.1371/journal.pone.0072192 ↗
9. 10.1002/smll.20160181510.1002/smll.201601815 ↗
10. 10.1039/C9NR08186K10.1039/C9NR08186K ↗
11. 10.1021/acs.molpharmaceut.0c0041110.1021/acs.molpharmaceut.0c00411 ↗
12. 10.5958/2231-5691.2015.00023.410.5958/2231-5691.2015.00023.4 ↗
13. 10.1016/j.apsb.2018.06.00510.1016/j.apsb.2018.06.005 ↗
14. 10.32474/DDIPIJ.2018.01.00012510.32474/DDIPIJ.2018.01.000125 ↗
15. 10.1016/j.cis.2013.11.01810.1016/j.cis.2013.11.018 ↗
16. 10.1016/j.ejpb.2018.03.01310.1016/j.ejpb.2018.03.013 ↗
17. 10.1016/S1773-2247(12)50046-810.1016/S1773-2247(12)50046-8 ↗
18. 10.1021/bm800276d10.1021/bm800276d ↗
19. 10.1016/j.ejpb.2018.05.01010.1016/j.ejpb.2018.05.010 ↗
20. 10.1016/j.colsurfb.2016.10.05210.1016/j.colsurfb.2016.10.052 ↗
21. 10.1039/C9NR09934D10.1039/C9NR09934D ↗
22. 10.1021/acsami.8b2082110.1021/acsami.8b20821 ↗
23. 10.1016/j.ejpb.2018.03.01310.1016/j.ejpb.2018.03.013 ↗
24. 10.1016/j.bbamem.2008.07.02910.1016/j.bbamem.2008.07.029 ↗
25. 10.1021/ma010804e10.1021/ma010804e ↗
26. 10.1248/bpb.32.145310.1248/bpb.32.1453 ↗
27. 10.1155/2014/95974110.1155/2014/959741 ↗
28. 10.1021/bm005649a10.1021/bm005649a ↗
29. 10.1134/S0965545X1802013X10.1134/S0965545X1802013X ↗
30. 10.1016/j.carbpol.2006.03.00810.1016/j.carbpol.2006.03.008 ↗
31. 10.1016/j.carbpol.2006.01.00110.1016/j.carbpol.2006.01.001 ↗
32. 10.1016/j.colsurfb.2012.10.03610.1016/j.colsurfb.2012.10.036 ↗
33. 10.1016/j.colsurfb.2010.08.00410.1016/j.colsurfb.2010.08.004 ↗
34. 10.1016/j.colsurfb.2012.10.03610.1016/j.colsurfb.2012.10.036 ↗
35. 10.1016/j.bioactmat.2021.08.00710.1016/j.bioactmat.2021.08.007 ↗
36. 10.1039/C4CS00487F10.1039/C4CS00487F ↗
37. 10.3389/fphar.2022.88037710.3389/fphar.2022.880377 ↗
38. 10.2147/IJN.S38449410.2147/IJN.S384494 ↗
39. 10.3389/fnut.2021.58846610.3389/fnut.2021.588466 ↗
40. 10.1016/j.ejpb.2014.03.01710.1016/j.ejpb.2014.03.017 ↗
41. 10.1002/nano.20220002710.1002/nano.202200027 ↗
42. 10.1016/j.bios.2020.11251010.1016/j.bios.2020.112510 ↗
43. 10.1021/acsomega.9b0208610.1021/acsomega.9b02086 ↗
44. 10.1039/C3CC48130A10.1039/C3CC48130A ↗
45. 10.1021/mp800137z10.1021/mp800137z ↗